Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications

[1]  M. Masucci,et al.  Regulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization , 2017, Viruses.

[2]  John G Doench,et al.  CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. , 2017, Cell host & microbe.

[3]  Fei Wang,et al.  Alternative Splicing of hTERT Pre-mRNA: A Potential Strategy for the Regulation of Telomerase Activity , 2017, International Journal of Molecular Sciences.

[4]  A. Celeghin,et al.  Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells , 2016, Cell Death and Disease.

[5]  V. Tergaonkar,et al.  Reactivation of telomerase in cancer , 2016, Cellular and Molecular Life Sciences.

[6]  Massoud Amanlou,et al.  Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays , 2015, J. Chem. Inf. Model..

[7]  T. Cech,et al.  Human telomerase: biogenesis, trafficking, recruitment, and activation , 2015, Genes & development.

[8]  A. Celeghin,et al.  Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus , 2015, Cell Death and Disease.

[9]  Z. Novalić,et al.  Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma , 2015, Journal of Cancer Research and Clinical Oncology.

[10]  D. Nadal,et al.  Telomerase Activity Impacts on Epstein-Barr Virus Infection of AGS Cells , 2015, PloS one.

[11]  E. Kieff,et al.  Epstein–Barr virus latent genes , 2015, Experimental & Molecular Medicine.

[12]  J. Mertz,et al.  Regulation of the latent-lytic switch in Epstein-Barr virus. , 2014, Seminars in cancer biology.

[13]  D. Dittmer,et al.  Zidovudine-based lytic-inducing chemotherapy for Epstein–Barr virus-related lymphomas , 2014, Leukemia & lymphoma.

[14]  Xiangjian Luo,et al.  Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity , 2014, Cancer biology & therapy.

[15]  E. Klein,et al.  Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. , 2013, Seminars in cancer biology.

[16]  A. Carbone,et al.  Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. , 2013, Seminars in cancer biology.

[17]  Xin Yu,et al.  Overexpression of human telomerase reverse transcriptase promotes the motility and invasiveness of HepG2 cells in vitro. , 2013, Oncology reports.

[18]  M. Masucci,et al.  Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein–Barr virus , 2013, Oncogene.

[19]  A. Celeghin,et al.  hTERT Inhibition Triggers Epstein–Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies , 2013, Clinical Cancer Research.

[20]  D. Gomez,et al.  AZT as a telomerase inhibitor , 2012, Front. Oncol..

[21]  Z. Novalić,et al.  Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors , 2012, Clinical Cancer Research.

[22]  F. Uher,et al.  Combined introduction of Bmi-1 and hTERT immortalizes human adipose tissue-derived stromal cells with low risk of transformation. , 2012, Biochemical and biophysical research communications.

[23]  G. Mukherjee,et al.  Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties , 2012, Oncogene.

[24]  Robert E. White,et al.  Latent Epstein-Barr Virus Can Inhibit Apoptosis in B Cells by Blocking the Induction of NOXA Expression , 2011, PloS one.

[25]  James M. Roberts,et al.  Separation of telomerase functions by reverse genetics , 2011, Proceedings of the National Academy of Sciences.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  S. Kenney,et al.  The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production , 2010, Journal of Virology.

[28]  G. Klein,et al.  Chromosomal rearrangements after ex vivo Epstein–Barr virus (EBV) infection of human B cells , 2010, Oncogene.

[29]  B. Han,et al.  Sustained viral activity of epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines , 2009, Molecules and cells.

[30]  Wilhelm Palm,et al.  How shelterin protects mammalian telomeres. , 2008, Annual review of genetics.

[31]  M. Pomper,et al.  Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors , 2008, Nature Medicine.

[32]  A. De Rossi,et al.  Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes , 2008, Journal of Virology.

[33]  R. Bertorelle,et al.  hTERT inhibits the Epstein‐Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV‐driven lymphomagenesis , 2007, International journal of cancer.

[34]  C. Klein,et al.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.

[35]  E. Blackburn,et al.  Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging , 2006, Nature Medicine.

[36]  Y. Zeng,et al.  siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. , 2006, Cancer letters.

[37]  G. Barber,et al.  Azidothymidine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphoma , 2005 .

[38]  R. Kitamura,et al.  Telomere size and telomerase activity in Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt’s lymphoma cell lines , 2005, Archives of Virology.

[39]  T. Kanda,et al.  Critical Role of Epstein-Barr Virus (EBV)-Encoded RNA in Efficient EBV-Induced B-Lymphocyte Growth Transformation , 2005, Journal of Virology.

[40]  Noriko Shirata,et al.  Epstein-Barr Virus Lytic Replication Elicits ATM Checkpoint Signal Transduction While Providing an S-phase-like Cellular Environment* , 2005, Journal of Biological Chemistry.

[41]  S. Fischer,et al.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. , 2004, Journal of the National Cancer Institute.

[42]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[43]  X. Deng,et al.  Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. , 2004, Journal of experimental & clinical cancer research : CR.

[44]  T. Ide,et al.  Steps Involved in Immortalization and Tumorigenesis in Human B-Lymphoblastoid Cell Lines Transformed by Epstein-Barr Virus , 2004, Cancer Research.

[45]  C. Deppmann,et al.  EBNA2 and Activated Notch Induce Expression of BATF , 2003, Journal of Virology.

[46]  I. Lampert,et al.  Promiscuous expression of Epstein‐Barr virus genes in Burkitt's lymphoma from the central African country Malawi , 2002, International journal of cancer.

[47]  S. Kenney,et al.  Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. , 2002, Cancer research.

[48]  N. Mitin,et al.  B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos , 2000, Oncogene.

[49]  S. Kenney,et al.  Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. , 1999, Cancer research.

[50]  E. Lavi,et al.  Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[51]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[52]  Rajiv Kumar,et al.  TERT promoter mutations in telomere biology. , 2017, Mutation research.

[53]  J. Yang,et al.  Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell-like traits in cancer cells , 2013, Oncogene.

[54]  M. Hande,et al.  hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. , 2011, Cancer research.